Sheet

PTO/SB/08A (10-96)
App: for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, go persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

AUG 0 2 2000

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known

Application Number 09/393,590

Filing Date 09/09/1999

First Named Inventor MOYER, Elizabeth

Group Art Unit 1645

Examiner Name S. Devi

Attorney Docket Number 211-US-NEW

				U.S. PATENT DOC	UMENTS	
Examiner nitials*	Cite No.1	U.S. Patent (Cocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
58	AA	5,721,215		Aoki, K.R. et al.	02/24/1998	\
48	AB	5,053,005		Borodic, G.E. et al.	10/01/1991	<u> </u>
<u>4₹</u>	AC	4,932,936		Dykstra, D.D. et al.	06/12/1990	
48	AD	5,696,077		Johnson, E.A. et al.	12/09/1997	
48	AE	5,437,291		Pasricha, P.J. et al.	08/01/1995	
49	AF	5,512,547		Johnson, E.A. et al.	04/30/1996	
48		5,766,605		Sanders, I. et al.	06/16/1998	
49		5,183,462		Borodic, G.E.	02/02/93	
97	ΑI	5,562,899		Gerber, A.	10/08/96	
		,				
7			$\overline{}$			
$\overline{}$		•	_			
\top						
1	Ì					
-						
	\	ĺ				
	\	<u> </u>				
	\sqcap	1				
	\vdash					
	 \					

			FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Foreign Patent Do	Cument Kind Code ^s (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
48	BA	WO 95/05842		Johns Hopkins Univ	03/02/1995		
49	BB	WO 93/05800		Allergan Inc.	04/01/1993		
	BC	WO 96/39167		Pearce, B.L.	12/12/1996		
	BD	WO 94/00481		Associated Synapse	01/06/1994		
				Biologics			1
50	BE	WO 97/35604		Wisconsin Alumni	10/02/1997		<u> </u>
			ĺ	Research Foundation			
60	BF	WO 96/11699		Wisconsin Alumni	04/25/1996		
$ abla^{\prime\prime}$				Research Foundation			$oldsymbol{ol}}}}}}}}}}}}}}}}}$

Examiner Signature	57	Date Considered	ocober 2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Applied for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE sons are required respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no AUG 0 2 2000 Substitute for form 1449A/PTO INFORMATION DISELOSU

STATEMENT BY APE

(use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number	09/393,590				
Filing Date	09/09/1999				
First Named Inventor	MOYER, Elizabeth				
Group Art Unit	1645				
Examiner Name	S. Devi				
Attorney Docket Number	211-US-NEW				

				U.S. PATENT DOC	JMENTS	
Examiner nitials	Cite No.1	U.S. Paten Number	t Document Kind Code² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					<u> </u>	
[
	_					
					1	

			FOR	EIGN PATENT DOCUMENT	·s	-	
Examiner Initials*	Cite No.1	Foreign Patent Docu		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
5 8	BG	0 593 176 A2		Wisconsin Alumni	09/28/1992		
				Research Foundation			
500	BH	WO 95/17904		Allergan, Inc.	07/06/1993		
47	BI	WO 95/17904		Allergan, Inc.	07/06/1995		
58	BJ	WO 94/28923		Allergan, Inc.	12/22/1994		
48	BK	WO 94/28922		Allergan, Inc.	12/22/1994		
5 7	BL	WO 95/28171		Mt. Sinai School of Medicine	10/26/1995		
69	BM	WO 95/17904		Allergan, Inc.	07/06/1995		
38	BN	WO 95/30431		Binder, W.J.	11/16/1995		
50	ВО	WO 96/39167	1	Pearce, B.L.	1123/12/1996		

_					_
ſ	Examiner	60	Date	. 0.9	9000
l	Signature	- Jy	Considered	0000pp	2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this b	Please	type a	plus	sign	(+)	inside	this	bo
---	--------	--------	------	------	-----	--------	------	----

AUG 0 2 2000

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.

ulerape	INOIN LEGITORI VICTOR	1990, NO personal gap required	to respond to a concession of unionna-	ton unicos it contento a valia si un contra ricinoci.
Substitute for form 1449B/PTO INFORMATION DISCLOSU STATEMENT BY APPLICA			(a) C	omplete if Known
		& TR	ADEN Application Number	09/393,590
INF	ORMATION	DISCLOSUR	Filing Date	09/09/1999
STA	TEMENT F	BY APPLICAN	First Named Inventor	Elizabeth MOYER
017	VI EINIEINI I	JI AII LIOAN	Group Art Unit	1645
	(use as many s	heets as necessary)	Examiner Name	S. Devi
Sheet	1	of 2	Attorney Docket Number	211-US-NEW

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
99	CA	FIRST, E.R., ET AL., "Dose Standardisation of Botulinum Toxin," The Lancet, vol. 343. p. 1035, (April 23, 1994).	
99	СВ	GARTLAN, M.G., ET AL., "Crystalline preparation of botulinum toxin type A (Botox): Degradation in potency with storage," Otolaryngology, vol. 108, p. 135-140, (1993).	
97	CC	HAMBLETON, B.C., ET AL., "Production, Purification and Toxoiding of Clostridium Botulinum Type A Toxin," Biomedical Aspects of Botulism, Academic Press (US), p. 247-260, (1981).	
47	CD	KADIS, S., ET AL., "Microbial Toxins," Bacterial Protein Toxins, Academic Press (US), p. 1-68, (1971).	
59	CE	LAMANNA, C., ET AL., "The Isolation of Type B Botulinum Toxin," Journal of Bacteriology, (US), vol. 54, p. 575-584, (1947).	
97	CF	MELLING, J., ET AL., "Clostridium Botulinum Toxins: Nature and Preparation for Clinical Use," Eye, vol. 2, p. 16-23, (1988).	
57	CG	SCHANTZ, E.J., ET AL., "Microbiological Methods," Journal of the AOAC (UK), Association of Official Analytical Chemists, Vol. 61 (No. 1), p. 96-99, (1978).	
9	СН	SCHANTZ, E.J., ET AL., "Quality of Botulinum Toxin For Human Treatment," Botulinum and Tetanus Neurotoxins, B.R. Dasgupta, ed., Plenum Press, p. 657-659, (1993).	
57)	CI	SLOOP, R.R., MD, ET AL., "Human response to botulinum toxin injection: Type B compared with type A,", The American Academy of Neurology (US), vol. 49, p. 189-194, (July 27, 1997).	
97		SUGII, S., ET AL., "Correlation Between Oral Toxicity and In Vitro Stability of Clostridium botulinum Type A and B Toxins of Different Molecular Sizes," Infection and Immunity, American Society of Microbiology (US), vol. 16, p. 910-914, (1977).	
59	CK	WRIGHT, G.P., "The Neurotoxins of Clostridium Botulinum and Clostridium Tetani," Pharmacology, vol. 7, p. 413-465, (1955).	

Examiner Signature	Date Considered	redoxo	2000
--------------------	--------------------	--------	------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Diagon		-1	oine :		. incido	thic	hov
Please	type a	pius	sign ((*.) inside	บนร	COX

_	OIPE	`
+	_ AUG 0.2 2000 .	7

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449B/PTO			Complete if Known		
00000		I DISCLOSUREM	Application Number	09/393,590	
INF	ORMATION	I DISCLOSU RE	Filing Date	09/09/1999	
STATEMENT BY APPLICANT			First Named Inventor	Elizabeth MOYER	
0		DI AII LIOANI	Group Art Unit	1645	
(use as many sheets as necessary)			Examiner Name	S. Devi	
heet	2	of 2	Attorney Docket Number	211-US-NEW	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
59	CL	SCHANTZ, E.J., ET AL., "Dose standardisation of botulinum toxin," The Lancet, vol. 335, p. 421, (1994).	
579	СМ	TSUI, J.K.C., ET AL., "Botulinum toxin type B in the treatment of cervical dystonia: A pilot study," Neurology, vol. 45, p. 2109-2110, (1995).	
			ļ
	1		
		\.	
Examine Signatur		Date Considered October &	øDD

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Corbetit	ute for form 1449B/PTO		Complete if Known		
			Application Number	09/393,590	
INF	NFORMATION DISCLOSURE	Filing Date	09/09/1999		
STATEMENT BY APPLICANT			First Named Inventor	Elizabeth MOYER	
917	AILMEN DI A	LIOAN	Group Art Unit	1645	- 10
(use as many sheets as necessary)			Examiner Name	S. Devi	MEA
Shoot	1 of 1		Attorney Docket Number	211 LIC NEW	

	Sileer	l T	211-US-NEW
OIP			OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
SIPZ	7		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
62120	Examiner [hitials	Cite No.1	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RADEM	HOY)	СМ	MOYER, E.D. ET AL., "Effects of Intramuscular Injection of Botulinum Toxin Type B in Nonhuman Primates," Botulinum and Tetanus Neurotoxins, Plenum Press (US), p. 655-656, (1993).
	579	CN	LEW, M.F. ET AL., "Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia" Neurology (US), vol. 49, p. 701-707, (1997).
	57	со	PREVOT, A.R. ET AL., "New Studies on Botulism and its Five Toxin Types," Annals of the Pasteur Institute (FR), vol 85, p. 2-20, (1953).
,			
•			
	Examine Signature		Date Considered October 2000

Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.